“All done!”

Evaluate, test and treat in one visit.



Clear results in 15 minutes or less.
5 tests for respiratory infection.
1 point-of-care device.*

Between sick children, worried parents, and busy waiting rooms, your time is critical for optimizing comfort and care. Help simplify workflows and minimize wait times with rapid results from the BD Veritor™ Plus System.

Make the most of each appointment with a compact, portable solution that reliably tests for COVID-19 & Flu A+B†, COVID-19‡, Flu A+B, Group A Strep and RSV.

Get more done in one at
bdveritor.com

BD

BD Veritor™ Plus System

Enhance care for pediatric patients and their families

Every parent's greatest worry is a sick child. Give your young patients and their families increased peace of mind by reliably identifying common pediatric respiratory infections on one compact, portable analyzer.

Rapid, reliable results

Differentiate between respiratory infections with overlapping symptoms in 15 minutes or less*.

Versatile diagnostic capabilities

Run a variety of respiratory tests on a single instrument.

Intuitive and connected

Help simplify diagnostic workflows with clear, connected digital results.

Contact your authorized distributor partner or BD to learn more.
For expedited service, say **Veritor** at the prompt. **1.844.823.5433**

*Result processing times for each BD Veritor™ assay are 15 minutes for the SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays, 10 minutes for Flu A+B and RSV assays, and 5 minutes for the Group A Strep assay.

†**For SARS-CoV-2:** In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

‡**For SARS-CoV-2 & FLU A+B:** In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152, U.S.
1.800.638.8663

bd.com